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INTRODUCTION 
'. 
The intrace_llular mechanisms underlying- steroid i 
regulation of target cells are not fully understood. 
However, important events in the regulation appear to be 
steroid entry into cells of the specific target tissue, 
interaction of the steroid with its specific cytosol 
receptor, and translocation of the steroid-receptor 
complex_ to the c_ell nucleus. Presumably this leads to 
initiate messenger RNA (ribonucleic acid) and protein 
synthesis (Figure 1). 
An important factor in establishing. the currenti 
understanding of the mechanism of steroid hormone action 
I 
was the- synthesis of isotopica·lly labeled compounds, . they 
provided the first molecular probes to discern the 
sequence of events that occur following the interaction 
- ' 
of a steroid hormone with a target cell (Jensen and 
Jacobson,1962). The use of tritium (3H) labeled compounds 
has also become very prominent in estrogen receptor 
studies involving breast cancer. 
An increased incidence of new cases of breast cancer 
annually in the United States and numbers of deaths due 
to the disease has created a greater interest towards 
studies evaluating estrogen receptors and their role in 
treatment of malignant and benign tumors. Wi tlif.f (11977) 
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Figure 1. Mechanism of action of steroid hormones. 
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suggests t:hat a tissue demonstrating estrogen receptors 
' 
should be classified as an estrogen target and shoul~ 
I 
I 
require hormone for maintenance and growth. Removal1of 
estrogen should result in regression or involution of the 
tissue. In contrast,· tissue lacking estrogen .receptbrs 
should not be effected by removal of endogeno..is hormone. 
The first evidence of a relations~ip between the associ-
ation of 3H hormones with a breast tumor and the clinical 
response of .the patient to ablative hor.mone therapy was· 
shown by Folca and associates in 1961 (Folca, Glascock, 
and Irvine, 1961). Other r~search also substantiates 
Witliff's proposal showing that 25.:.40% of patients with 
inoperable breast cancer have neoplasms that regress, 
after either the administration or pharmacological c~n­
centrations of hormones, such as androgens and estrogens, 
or removal of endogenous hormones, such as by .ovarie.ctomy 
or adrenalectomy (.Kennedy, 19 7 4) • These findings suggest 
! . 
that some malignant breast tumors may be hormone 
dependent. 
The concept underlying endocrine therapy is that 
certain twnor cells have retain!=d their ability to respond 
to the same hormonal stimuli as·their normal progenitor 
cells (Witliff, 1977). It is therefore suggested that . . 
the presence of specific estrogen receptors in human. 
breast carcinomas may be predictive of a patient's 
4 
response to endocrine therapy (Garola and McGuire, 1978, 
Witliff, 1977, and McGuire, 1975). 
h ·d · · h I Ot er steroi receptors are also present in uman 
I 
I . . 
breast cancer. cells and may provide additional information. 
For example, Horwitz et .al (1975) predict that the pre-
sence of progesterone receptors in a tissue snould ~e an 
. ' 
even more sensitive indicator of potential responsiveness 
to endocrine· therapy than the estrogen receptor. The 
basi.s for .such a prediction i.s the underlying concept 
that progesterone effects require estrogen priming, 
thereby inducing the synthesis of the progesterone 
receptor (Figure 2). 
Estradiol (E 2 ) 
mRNA 
Figure· 2. Induction of progester.one receptor by 
estradiol (McGuire et al, 1978). 
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Thus; the presence of progesterone receptors in, a 
" tumor would indicate that the entire sequence, involving 
estrogen binding to a cytoplasmic receptor, movement! of 
I 
I 
the receptor complex into the nucleus, and stimulation 
' 
of a specific end product, can be achieved in a tumor 
cell. This would rule out the existence of a defect be-
yond the binding step (McGuire et al, 19.78). Therefore, 
the presence of progesterone receptors in cancerous ' 
tissue will show that the tumor remains under at least 
partial endocrine control and may be classified as endo-
crine responsive. In support of the prediction, reiearch 
i 
showed 56% of tumors with estrogen receptors also had 
progesterone receptors, and tumors without estrogen ' 
receptors also .lacked progesterone receptors (Horwit,z 
et al,· 1975). Preliminary 'data show only those breast 
tumors with progesterone receptors regressed after 
endocri'ne therapy. Continua ti on of estrogen and prq-
gesterone receptor studies together with research d~rected 
toward the evaluation of other steroid receptors pr~sent 
in.human breast carcinomas, such as androgens and gluco-
corticoids may give hope of treatment for those patients 
I 
with estrogen-receptor positive but unresponsive tumors. 
In research by McGuire (1977), it was shown in 
randomly tested human breast tumors that 75% were 
estrogen-receptor positive (ER+), with 74% of .the ER+ 
.. 
tumors also having progesterone receptors (PgR) and 
9% of the ER- tumors having PgR. Where primary versus 
I 
metastatic tumors were examined, 77% of the primary 1 
I 
tumors were.ER+ with 77% of them containing PgR and '66% 
I 
6 
of the metastatic tumors with ER+ with only 59% of them 
having PgR (Figure 3). 
Danazol is an isoxazole derivative of the synthetic 
steroid 17 a-ethinyltestosterone (Figure 4). It acts 
through the suppression of.gonadal function .(Chamness 
et al, 1980), and may possibly be used in future treat-
. - - . 
I 
ment of hormonally dependent cancers, particularly those. 
of the breast and endometrium (Jenkin, 1980). Suppqrt 
for the use of danazol was strengthened by the reported 
increased incidence of breast cancer in patients with a 
history· of benign breast .diseases (Humphrey and Swe:z:;dlow, 
·1962, Davis et al, 1964, Veronesi and Pizzocaro, 196
1
8, and 
I 
Dmowski and Cohen,. 1978), and the fact that danazol 'has 
been shown to .cause relief of various disorders of the 
breast (Greenblatt et al, 1971, Lauersen and Wilson,! 
1976, Asch and Greenblatt, 1977, and Blackmore, 1977a). 
The attempts to show differences between estrogen 
receptors in normal human breast.tissue and fibrocystic 
tissue have thus far been unsuccessful (Terenius et :al, 
1974).' 
;_ ~. 
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Figure 3. Swrunary of distribution of ER and PgR in human breast tumors (McGuire, 
1977). 
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In recent studies, danazol has been demonstrated to 
have four major· pharmacologic effects: (1) direct 
inhibition of gonadotropin synthesis and/or release ' 
(Lauersen and Wilson, 1977, Wood et al, 1975, and 
Eldridge, Dmowski and Mahesh, 1974); (2) direct inhibition 
of multiple enzymes of steroidogenesis (Barbieri et al, 
1977, and Barbieri, Camick and Ryan, 1977); (3) inter-
action with androgen, glucocorticoid and progestero~e 
receptors in target tissues (Barbieri, Lee and Ryani 1979, 
and Chamness, Asch and Pauerstein, 1980); and (4) alter-
ation of endogenous steroid metabolism (Barbieri, Lee and 
Ryan, 1979, and Barbieri and Ryan, 1981). The majority 
of studies exclude pinding to the estrogen· receptor as a 
possible method of action (Krey, Robbins and McEwen; 1981, 
Chamness, Asch and Pauerstein, 1980, Barbieri et al; 1979, 
Creange, Potts and Schane, 1979, Woods et al, 1975, 
--- --
Dmowski et al; 1971, and Potts et al, 1974). 
In further examination of danazol's antigonadotropic 
action, Chamness, Asch and Pauerstein (1980) studied its 
_ability to bind and translocate androgen, estrogen and 
progesterone receptors both in vivo and in vitro in· the 
rat. Their results showed danazol bound to the proges-
terone and androgen receptors, however, only the androgen 
receptor was translocated to the nucleus at effective 
antigonadotropic doses. 
., 
; 
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To further understand Xhe mechanism of danazol'·s. 
action in its target cells, the following in vitro study 
-.- i 
was performed to (1) determine the specificity of danazol 
b · d · 1 b · · .b · d · I in ing to cytoso receptors y competitive in ing e~-
periments, (2) evaluate the dose response relationship of 
danazol, and (3) determine the specificity for danazol to 
translocate receptors into the nucleus. In addition, 1 an· 
I 
in vivo experiment was conducted to study the effects of 
danazol of cytoplasmi~ steroid receptors.in uterine,mam-
. 
marian, hypothalamic, and adrenal tissue. Although this 
research is done on non-cancerous tissue, the implications 
will be beneficial in future study of rat and human carcinoma. 
MATERIALS AND METHODS 
Animal Care 
' 
Nineteen Sprague-Dawley female rats ranging 200,225. 
grams in weight, were obtained from Harlan Industrie's, 
Indianapolis, Indiana. Prior to being sacrificed, they 
I 
were maintained for two weeks in animal quarters on 
Purina Lab Chow (Ralston-Purina Co.) and tap water .ad --
libitum. 
Tissue Preparation 
The rats were stunned, decapitated, exsanguated and 
five tiss·ues (uterus, mammary adrenals, hypothalamus and 
pituitary) were removed from each. Irrunediately upori 
excision, each tissue was placed on a chilled glass 
plate, trimmed of excess fat with a razor blade, weighed 
and quick frozen in dry ice and acetone. Each tissue was 
wrapped .individually in foi.l, labeled and stored in ·a 
freezer for future competitive binding and dose-response 
.experimen.ts. 
For in vitro nuclear translocation experiments, 
uteri from fourteen pre-puberal ana thirteen post-p~beral 
' Sprague-Dawley rats were excised using the same method as 
mentioned above. After being trimmed of excess fat; the 
uteri were incubated in media consisting of 1 ml mimimal 
10 
essential.media with Earle's salts and L-glutamine 
' . ' 
' 
' 11 
(Grand Island Biological Co. ) · and 1 ml of Kreb' s Rin_ger 
Bicarbol).ate Glucose, pH 7.4 (Umbreit et·al, 1964). Forty 
microliters of indicated steroids in 100% ethanol were 
added to give ~ final concentration of 2 x l;-s M an~ the 
uteri·were incubated for two hours at 37°c with gentle 
bubbling of 95% osygen: 5% carbon dioxide in a Dubnoff 
Metabolic Shaking Incubator (GCA Precision Scientific) . 
Controls were incubated with 100% ethanol. After incu-
pation,· the tissue was blotted, weighed and quick frozen 
in dry ice and acetone for later assay. 
Isolation of Cytosol and Nuclear Receptors 
All procedures were done· on ice.and/or in a 
refrigeration unit at 4°c, unless specified otherwise. 
Centrifugations were carried out (depending on the pro-
cedure, sample size and rpm speci.fication) in either a 
Beckman "Airfuge", International Refrigerated Centri,fuge, · 
' 
Model B-20 (International Equipment Co.) or an Adams 
: 
Sero-fuge·. Where microli ter volumes were required, , 
~utomatic micro-pipets (Oxford laboratories) were used. 
Isolated cytosol ~nd nuclear receptors were prepared 
by a modification of the "methods of Williams and Gorski 
(1974), Chamness et al (1979), and Pavlik and Coulson 
(1976) ·• Frozen tissue was cut into small pieces and then 
homogenized in phosphate buffer .[P-buffer (5mM sodiufn 
, 
phosphate-, pH 7. 4, lrnM thioglycerol, 10% ·glycerol) l, in 
a seven milliliter Ten Broeck pyrex glass-glass ti~sue 
grinder (about 100-150 mg tissue/ml P-buffer). The 
. ' 
homogenate was centrifuged (Adams Sero-fuge) eight-~ 
' 
minutes at 1000 .x g; the supernatant was taken. as the 
cytosol, while the pellet was resuspended in P-buffer 
and·recentrifuged twice, then resuspended for one hour 
in buffer with 0.4 M potassium chloride to extract 
receptors from the nuclei. The pellet was then· centri-
fuged for 10 minutes at 2000 x g (International 
.) 
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Refrigerated Centrifuge) and the supernatant was assayed 
for· nuclear receptors. 
Receptor Incubations 
Duplicate 200 µl aliquots of cytosol or nuclear 
extract were added to SO µl of radioactive ligand, ,while 
another duplicate 200 µl aliquots were added to 50 µl o·f 
the same ligand with an excess of non-radioactive 
competitors for determination of non-specific binding. 
In addition, to measure total counts, duplicate 200, µl 
·aliquots of P-buffer were added to 50 µl of radioac,tive 
ligand. Final concentrations of radioactive ligand.s 
. -10 ' 
(New England Nuclear) were 5 x 10. M [2,4,6,7,16,,17-
3 -10 H(N)] estradiol (137.1 Ci/mmole), 5 x 10 M [l,2•,4,5, 
6,7,1G,l7- 3H(N)] dihydrotestosterone (179.0 Ci/mmo~e), 
-lC 3 5 x. 10 M [1,2,6,.7- H(N)] progesterone (101.0 Ci/mmole), 
13 
5 x 10-lO ~ [l,2,6,7- 3H(N)] corticosterone (105.0 
·•.l,c. Ci/mmole). Non-radioactive competitors were 1. 67· x 10-? 
M diethylstibesterol, 1.67 x 10-? M dihydrotesto~ter~ne, 
' -1. ' -7 
1.67 x 10 M progesterone, and 1.6'7 x 10 M 
corticosterone (all are final concentrations) . Incu-
· bations for cytoplasmic receptors were all three hours 
at o0 c, while those for nuclear receptors' were three 
hours at 30°c (estrogen) or 18 hours at o0 c (a'ndrogens, 
· progestins·and corticosteroids). Cytosoi and nuclear 
extract were saved (50 µl samples) for protein 
determinations. 
Binding Competition Experiments 
I 
Cytosol was prepared in P-buffer from uteri, mammary, 
adrenal, hypothalamic and pituitary tissue (assayed 
separately). Duplicate aliquots of 200 µl of cytosol 
were incubated with 50 µl of radioactive steroid in , 
buffer plus 50 itl of varying concentrations· of danazol. 
The danazol ·(Danocrine) was a gift from Sterling-Winthrop 
Research Institute. Binding was assayed by the hydro-
xylapatite method (HAP) and non-specific binding was1 
subtracted. 
Dose Response Experiments 
Cytosol was prepared in P-buffer from uterine 
tissue. Triplicate aliquots of 200 µl of cytosol were 
-' -
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incubated ,with 50 µl of varying concentrations of 
radioactive ligand, Competitive binding was checked' 
' . I 
with 50 µl of non-radioactive ligand added to one aliquot. 
I 
. ' 
I 
In addition, triplicate aliquots of 50 µl of radioactive 
ligand were incubated with varying microliter concent 
trations of cytosol, with 50 µl of non-radioactive 
competitor in one aliquot to check competitive binding .• 
Assay for binding Was by the HAP method and non-spec~fic 
binding was subtracted. 
Nuclear Translocation. Experiments 
Nuclear extract was prepared in P-buffer from uteri 
' 
of pre- and post-pµberal rats. In experiments with the 
' ' pre-puberal uteri, triplicate 200 µl aliquots of the' 
' I 
nuclear extract from control, danazol and dihydro- ' 
' testosterone (DHT) incubated tissues were added to 50 
µl aliquots of radioactive DHT with a triplicate also 
containing 50 µl of non-radioactive DHT. ) 
I 
Post-puberal uterine experiments were performed!, 
I 
. . I 
using triplicate 200 µl aliquots of the nuclear extr~ct 
. . i 
from control, .danazol, DHT, progesterone, corticosterone 
' and ~stradiol incubated uteri, with a 50 µl aliquot of 
' 
appropriate radioactive ligand. To check for competiti.ve 
binding a. triplicate aliquot of 200 µl nuclear extract 
from each incubation with 50 µl of radioactive· steroid 
I 
9lus 50 µl of non-radioactive competitor was performed. 
I 
Hydroxylapatite Assay 
One milliliter of hydroxylapatite suspension I 
I . 
[2.5 grams of Bio-Rad HTP, DNA grade, per 100 ml of ITP 
I 
buffer (50 .m.."1 Tris and 10 mM KH 2Po 4 )] was added to each 
tube at the end of incubation and kept su.spended by :. 
occasibnal vortexing (Fisher Scientific Vortex-Genie) 
J 5 
for 30 minutes. The HAP was then centrifuged 1.5 minutes 
at 1000 x g, resuspended in 1.5 ml of fresh P-buffer, and 
recentrifuged; this wash was completed twice more. One 
milliliter of 100% ethanol was then added to each pellet 
to extract the radioactive steroid, which was then ~ounted 
in 5 ml of scintil"lation fluid (19 gm PPO and 1. 9 gl\l 
POPOP/3.8 L toluene). All counts were made in a Hewlett-
Packard Tri-Carb 300 scintillation counter at Maxey Flats 
Low-Level Nuclear Waste Disposal Site. 
Protein Assay 
Protein concentrations were determined by a mo~if i-:-
, 
' cation of the Lowry Method (Lowry et al, 1951). Toi 
precipitate proteins, cold 10% trichloroacetic acid1was 
added to 50 µl.of cytosol or nuclear extract in a 
cellulose nitrate tube (Beckman, 175 µl capacity) and 
centrifuged in a Beckman Airfuge at 20 psi for 5 minutes. 
I 
The supernatant was aspirated with a disposable tra~sfer 
pipet. To. the prate.in precipitate, 100 µl of. 3N. so?ium 
I 
hydroxide was added, stirred with a toothpick and s~t 
,j 
,j' 
i 
I 
.] 
aside for -10 minutes. Two concentr.ations ( 10 µ 1 and' 
50 µl) of the protein mixture and of a bovine serum I 
albumin standard (1 gm/ml) were added to separate te:st 
I 
tubes and brought to o~s ml.with distilled water. The 
remaining procedures were identical with those of Lowry 
et al (1951). Measurement of protein concentr·ations 
16 
were made in a Bausch and Lomb Spectronic 70, and protein 
was expressed in mg/ml. 
In Yivo Experiment . 
Twenty-four female S/D rats were divided into two 
groups. The first group was given daily intramuscul'ar 
(IM) inject{ons of dariazol (4 mg/kg body weight) 
suspended in Planters Peanut Oil. This treatment 
continued for fourteen days. The control group 
received daily IM injections of peanut oil only for 
fourteen days. On treatment day nine, bilateral 
ovariectomy was performed on eight of the twelve 
I 
expe~imental and control rats, leaving four intact ~n 
each group. Surgery was performed under anastbesia ! 
. ' 
using Sodium Nembutal (Abbot Laboratories), (4 mg/100; gm 
' 
body weight) injected intraperitoneally · (IP) . Sodiuni 
' 
Penicillin G 10 mg was inj"ected IM into each post- ·. 
operative rat. The ovariectomized group received an IM 
injection of 100 micrograms of estradiol benzoate·on 
treatment day twelve. 
I. 
Preparation of Tissu~ 
All animals were sacrificed on treatment day 
fourteen. .Tissues for assay· were immediately remove~, 
17 
tr-irnrned of excess fat, weighed to the nearest milligram; 
I 
' 
dropped into an iced, acetone-C0
2 
pellet bath, blotted, 
and kept frozen at -20°C until assays were ~erformed. 
' 
Preparation of Cytosol 
All reagents used for preparation of cytosol are 
listed in Table 1. Cytosol fraction was prepared by' the 
method derived by Heidemann and Wittliff for the Bec~man 
"Airfuge" (Heidemann and Wittliff, 1979). All tissues 
were prepared, in the same. manner.. The· frozen ·minced' 
tissue was homogeriized in cold phosphate bu~fe~ (2.0 ml/ 
gm tissue) with a Ten Broeck glass-glass homogenizer. 
All prepa~ations were kept on ice at all times. Using 
I 
I 
an Oxford adjustable sampler micropipetting system, 
0.175 ml of cytosol was added to pre-cooled cellulose 
I 
nitrate tubes (Beckman Instruments, Inc.) and placed!in 
i 
the pre-cooled (4°C) head of a fixed-angle rotor type 
. I 
I 
A-100 Beckman Airfuge (Beckman Instruments, (Inc._) and 
centrifuged at 110,000 x g (24 psi) for 10 minutes. 
Tbe protein concentration of the supernatant was . . 
confirmed later by" a modified Lowry method (Lowry, 
et al. , 1951). 
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T~BLE l 
REAGENTS 
Danazol Brandname Danocrine, gift of Sterl~ng­
Winthrop Research Institute: 
Hormones 
Hydroxylapatite 
Suspension 
3i-17~-est~adiol, progesterone, 
dihydrotestosterone, corticosteron~; 
dissolved initially in absolute 
alcohol then diluted with phosphate 
buffer (pH 7.4) to appropriate ' 
concentrations (New England Nuclear, 
Corp.). 
Diethylstibesterol, progesterone, 
dihydrotestosterone, corticosterone; 
dissolved initially in absolute 
alcohol then diluted to appropriate 
concentrations with phosphate buffer 
(pH 7.4) (Sigma Chemical, Co.). 
100 ml TP buffer plus 2.5 gm DNA-
grade Bio Gel HTP hydroxylapatite 
(Bio-Rad) , pH adjusted to 7. 2 •. 
' 
Phosphate Buffer 5 mM sodium phosphate, pH 7. 4; 1 
monothioglycerol; 10% glycerol. 
m¥ 
I Reagent A 
Reagent B 
2% Na2co3 in 
0.5% CaS04 ··5 
0.1 N NaOH. 
H20 in 1% Na or K tartrii.te. 
Reagent C 25 ml reagent A plus 0.5 ml reagent B 
(mixed fresh daily). · 
Reagent, D 1:1, Phenol Falin Reagent: distill~d 
water (mixed fresh daily). 
Scintiverse r™ Universal LSC Cocktail (Fisher 
Scientific, Co.). 
T_ris Buffer 50 mM Tris, .10 mM KH 2Po4 , I! 7.2 at 4°C. 
Wash Buffer ·Phosphate Buffer, pH 7.4; plus 1%; 
(V/V) Tween 80. 
Hydroxylapatite Micromethod 
All reagents used for the hydroxylopatite micro-
method are listed in Table 1. The Oxford adjustable, 
' micropipette system was used for all micropipettin~.: 
' "From pooled centrifuged supernatant (cytosol fraction), 
19 
0.05 ml aliquots were incubated in duplicate for four 
hours at 4°C in 0.45 ml polyethylene microtubes (Bio-Rad 
Laboratories) with .0.05 pmol (O.l ml of ~ x 10-lO) 3H-
labeled hormone in 0 .1 ml phosphate buff er. A paraL).el 
tube contained a 100-fold excess of competing unlabeled 
hormone. After incubation, 0.06 ml of hydroxylapatite 
(HAP) suspension was added to each microtube. After 
vortex, further incubation for 30 minutes was completed 
with gentle vortex every ten minutes. The microtubes 
'. 
were then centrifuged for 30 seconds in a pre-cooled' 
Adams-Sero Fuge centrifuge (Clay-Adams, Inc.) at 1000 x g. 
The pellets were washed twice with 0.2 ml wash buffe~, 
with centrifugation and gentle aspiration after each· 
wash. After the final wa~h, centrifugation and 
aspiration, the resulting pellet in the end of the-
microtube was cut off and dropped into a scintillation 
vial, Scintiverse I (Fisher Scientific, Co.) or Insta 
Gel (Packard) scintillation Cocktail (10 ml) was add~d to 
each vial and all vials were counted for radioactivity in 
a Packard Tri-carb liquid scintillation counter (Model 
300-C). This method is summarized in Figure 4. 
,. 
•.' 
~-... 
Sacrifice S/D Rat 
+ 
Remove tissue, weigh, freeze 
+ 
Homogenize in P0 4 buffer (2 ml/gm tissue) 
+ 
Centrifuge 100,000 x g for 10 minutes 
+ 
Supernatant (cytosol fraction) 
+ 
Hydroxylapatite assay· 
" a. Cytosol (0.05ml) 
'plus 
b. Cytosol (0.05 ml) 
plus 
I 
l 
I 
I 
I 
! • 
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3 0.10 ml H-compound 
(duplicate) 
Incubate 4 hrs., 4°C 
O .1 ml ·3H-compound pl us 
(lOOx excess) competitor 
I 
Incubate 4 hrs., 4°C 
Add hydroxylapatite 0,06 ml 
Incubate 30 min., 4°C 
Vortex every 10 min. 
+ 
Wash 2 x, 0.2 ml 
Buff er - Tween 80 
. + 
Centrifuge 1000 x g, 30 sec. 
+ 
Cut tip off with pellet 
+ 
Count in Liquid Scintillation Counter 
'. Hydroxylapatite Micromethod 
Figure 4 . 
RESULTS 
To evaluate the validity of the HAP assay and to 
determine conditions ·to be used in later experiments, 
titration curves were run for both 3u-estradiol and 
cytosol. Specific activity was measured in counts per· 
minute/mg of protein. Figure five shows a dose~response 
relationship when the concentration of 3H-estradi~l was 
' reduced in the incubate, in the presence of 200 µl of , 
. . 
cytosol. Likewise, by the condition of increasing 
amounts of cytosol, the expected dose relationship was· 
seen in specific activity. This indicates as the cytosol 
.was increased, the amounts of cytosol receptors were 
'increased, therefore the increase in specific binding .. 
' 
From these data, experimental protocol for all succeeding 
experiments called for the use of 10-9 M estradiol and 
200 µl cytosol. 
In the first series of experiments performed, the 
competition for steroid receptors with increasing doses 
of danazol were performed in various tissues. The 
r·esults of these experiments are shown in figures six~ 
seven, eight and table two, and.Bre expressed as a 
percent of control binding. In all experiments, danazol 
exhibited a dose-response competition with steroid 
receptors. Figure six shows that in mammary tissue, 
competition with the androgen receptor exceeded all 
.•21 
,. , 
~·· 
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other steroid receptors. Binding was 58% of the control 
at the physiological concentration of 10~ 9 M danazol 
I 
compared .to 88% of the control values of estradiol. l 
Danazol was the most efficient comoetitor of the androgen 
, • I 
' 
receptor in uterine tissue, with.a value of 80% of ihe 
·control ·at 10-9 M (Figure 7). The competition for 
steroid receptors in pooled adrenal tissue is. shown in 
figure eight. This figure shows poor competition with 
-9 all steroid receptors at 10 M danazol and strong 1 
' -5 
competition at the pharmacological dose of 10 M. 
Due to the lack of cytosol for hypothalamic tissues, 
only two assays were performed. Using only the test 
-9 dose of 10 M, results show in table one that danazol 
' ' ' 
competedinost effectively with the DHT receptor (73% of 
•, 
control) followed by progesterone (86%), corticosterone 
: 
(90%) and estradiol (91%). 
Table z. Danazol competition for steroid receptorslin 
hypothalamic tissue. I 
I 
Incubation conditions· Estradiol DHT Progesterone Corticosi::erone 
Danazol (10- 9 M) 91* 73 86 90 
*Mean percent of cytosol alone which was taken as 100%. 
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Figure s; Danazol competition for steroid receptors in 
pooled adrenal tissue. 
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A single test was performed with pooled pituitary 
' --'if! cytosol, showing that danazol at 10- 9 M did compete with 
the DHT receptor (65% 0£ control). 
A comparison of steroid binding competition by 
danazol at 10- 9 M is seen in table three. This table 
summerizes the data that danazol competes more favorably 
with the androgen receptor in all tissues with a mean of 
76% of the control followed by estradiol (91%), 
progesterone (92%), and corticosterone'(951) .. 
In vitro translocation experiments of steroid cytosol· 
receptors were performed to better de_termine receptor 
specificity and biological ·function. The first experi-
ments were performed on 25 day old, pre-puberal uterine 
tissue and the results are·shown in table four. 
Compa·red to the control specific activity of 426 cpm/mg 
protein, incubation with 10-9 M DHT resulted in a 146% 
increase· over the control with a mean specific activity 
of 1050 cpm/mg protein (P<.l). 
-6 : 
Danazol at 10 M trans-
located the androgen receptor 85% over the control.! 
I 
_In all.experiments in which in vitro translocation 
was evaluated in adult uterine tissue, danazol did ~ot 
signficantly elevate nuclear receptors in any of the 
steroids tested (Table 5). Danazol translocated the DHT 
receptor most successfully with a value of 68% incr~ase 
over the control. Incubation with respective stero~ds 
'.r.a,ble 3. Comparison of steroid binding competition by danazol at 10-9 M. 
Competing 
Steroid Receptors Uterus Mammary Adrenal Hypothalamus 
Estradiol 92* 87 92 91 
DHT 80 58 9.3 73 
Progesterone 89 95 98 86 
Corticosterone 95 98 96 90 
*Mean percent of control binding. 
Mean 
91 
76 
92 
95 
N 
a:r-
. ' 
·' ' 
Table ~· In vitro t~anslocation of uterine androgeri 
receptor in pre-puberal rats. 
Treatment 
N=6 
Control 
DHT (l0- 9 M) 
Danazol (lo- 6 Ml 
Specific activity 
cpm/rng protein 
426±146* 
1050±762a 
790±483 
*Mean ± standard deviation 
a P<.l from controls 
Percent increase 
over control 
146 
85 
29 
' 
·•'#"' Table 5. 
I 
In vitrci translocation of uterine steroid 
'receptors in adult rats. 
Tre·atment 
'N=6· 
Control 
Estradiol 
Danazol 
Control 
DHT 
Danazol 
Control 
Progesterone 
Danazol 
Control 
Corticosterone 
Danazol 
Specific activity 
cpm/mg protein 
873±200* 
1983±.393a 
1041±491 
349±316 
971±354b 
585±692 
570:!:370 
1229±789 
694±528 
62±74 
95±47 
68±64 
* Mean ± standard deviation 
a P<.001 from control 
b P<.05 from control 
Perce~t incre~se 
.over control: 
127 
19 
178 
68 
116 
22 
53 
10 
30 
•,. 
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demonstrated that the cytosol recep~or was translocated, 
reflecting values that were significant for DHT (P<.05) 
and highly significant for estradiol (P<.001). 
The effect of 4 mg/kg of danazol for 14 days :can be 
seen in Table 6· Daily injections of danazol showed a 
highly significani reduction of uterine weight expressed 
either in absolute or relative weight terms in rats which 
had intact ovaries. Ovariectomized rats failed to·show a 
further reduction in weight after danazol injectioqs. 
The red~ction in uterine weight after ovariectomy is also 
highly significant (P < • 01). 
Table 7 indicates that danazol has an effect on 
reducing pooled adrenal weight in intact rats but shows 
no additive reduction in adrenal weight after ovarfectomy. 
Rats receiving daily injection of danazol (4 mg/kg 
body weight) for nine days had mean ovarian weights of 
130 ± 12 at the time of ovariectomy, compared to rats 
receiving only the vehicle (154 ± 20) as indicated .in 
' 
Table B. This reduction in ovarian weigh"!; was higtlly 
significant (P < • 02). 
The effects of danazol injections on steroid 
receptors in the uterus ls shown in Table 9 . Danazol 
treated rats show a non-significant decrease.in all 
receptors compared to intact rats with estrogen receptors 
' showing a 28% reduction. However, significant differences 
TABLE 6 
EXPERIMENT I 
EFFECT OF DANAZOL ON ABSOLUTE AND RELATIVE UTERINE WEIGHT 
Treatment Absolute 
Intact Control (n = 4) 
Intact * Danazol (n = 4) 
Ovariectomized Control (n = 8) 
* Ovariectomized Danazol (n = 8) 
*Danazol ~ 4 mg/kg/day for 14 days 
**Mean ± Standard Deviation 
a P < ,02 compared to Intact Control 
· b P < •. 01 compared to Intact Control 
686 
498 
498 
489 
Uterine Weight Relative Uterine Weight 
(mg) (mg/100 gm body weight) 
± 30** 224 ± 14 
± 50a 174 ± 16a 
± 85b 180 ± 28a 
± lOOb 176.± 3la 
' . 
TABLE 7 
·EFFECT OF DANAZOL ON ABSOLUTE AND RELATIVE POOLED ADRENAL WEIGHT 
Treatment 
Intact Control 
* Intact Danazol 
Ovariectomized Control 
* Ovariectomized Danazol 
Absolute· Adrenal Weight 
(mg) 
'** 70.3 
64.8 
57.3 
57 •. 1 
*Danazol = 4 kg/day for 14 days 
**Mean adrenal weight calculated from pooled adrenals 
Relative Adrenal Weight 
(mg/100 gm body weight) 
22.8 
23.5 
22.6 
23.7 
.. 
TABLE 8 
EFFECT OF DANAZOL ON ABSOLUTE OVARIAN WEIGHT 
Treatment 
Control (n = 8) 
* Danazol (n = 8) 
*Danazol = 4 mg/kg/day for nine days 
**Mean ± Standard Deviation 
a P < • 02 Compared to ovariectomized controls 
Absolute Ovarian Weight 
(mg) 
154 ± 20 ** 
130 ± 12a 
.. 
~; 
TABJ_,E 9 
PERCENT CHANGE IN RECEPTOR BINDING OF 3H-STEROIDS . 
AFTER DANAZOL INJECTIONS AND OVARIECTOMY 
Tissue Treatment E2 DHT PROG CORT 
intact 100 100 100 100 
+danazol * 28 + ** 17 + 23 + 13 + 
Uterus 
42 + a 10 + 25 + 4+ ovarx 
+"danazol 45 + a 20 + 24 + 8+ 
intact 100 100 100 100 
+danazol 2+ :I.l +. 5 + 2+ 
Mammary ovarx 12 + 7+ 8+ 3t 
. +danazol 15 + 12 + 10 + 10 + 
--- - - ---- - - injectecl.-a'f dose- ol .4 mg/kg/day- Ior.14 - - - -- - - - -- -----*Danazol days 
**Arrows refer to increase t or decrease+ in specific binding compared to intact 
control "' "' a Significant from·controls at P< .05 
- - - - ·-
' 
·.{fl 
I 
I 
were seen for estrogen receptors when the rats were 
I 
ovariectomized ( 42% reduction) and when these castra tie·d 
I 
rats received danazol {45% reduction). The ovariectomy 
i 
failed to reduce significantly the concentration of ~he 
other steroid receptors. Mammary tissue was not 
significantly changed in its ability to bind steroid 
receptors. 
Binding data fcir hypothalamic tissue and adrena~ 
glands were incomplete since they were analyzed· from ! 
pooled tissues. However, they demonstrated the general 
trend toward reduction of receptor binding. 
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DISCUSSION 
I 
I 
The mechanism of action of danazol at the sub-i 
' cellular level is not completely understood. ·However, 
I 
according to curren~ ideas of hormone action, danaz61 
should bind to a specif.ic cytosol receptor and trans-
locate it to the nucleus of that particular target cell, 
where it would initiate protei.n synthesis .. It has been 
well substantiated that danazol binds most efficiently. 
to the androgen receptor in various target tissues 
(Chamness et al, 1980 and Barbieri et al, 1979). It is· 
also suggested that danazol .has a somewhat low~i affinity 
for the progesterone (Chamness et al, 1980 and Barbieri 
et al I ·1979) and glucocorticoid receptor (Barbieri et al, 
1979), with little or no binding to the estrogen 
receptor (Krey et al, 1981, Chamness et al, 1980, Woods 
et al, .1975, Creange et al, 1979, Dmowski et al, 1971 and 
' -- 1' 
Potts et al, 1974). Results of this study are concurrent 
with these findings except for demonstrating a low ·, 
. affinity binding of danazol to the estrogen receptor. In· 
support of these data, Creange et al, (1979) has shown 
danazol competition with estrogen receptors of the 
pituitary. 
At physiological doses~ danazol competed simil~rly 
••Ii th the· estrogen i progesterone and glucocorticoid 
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receptor,·showing a somewhat better competition with the 
: 'Ji;"!· androgen receptor (Table 3) . in comparison, as 
concentrations of danazol were increased, there was ·an 
in.creased .competition for all receptors (Figures 6, 
·7, and 8) . 
'To check for receptor specificity and biological 
' 
function, in vitro translocation experiments were per-
formed on pre- and post-puberal rats. In vivo exper:i-
rnents by Chamness et al (1980) provides evidence that -- '' 
the androgen receptor is the only .one effectively tr'ans-
·1oc.ated to the nucleus by danazol. The findings of 'this 
rese.arch, in contrast, show a non-statistical tendency 
of danazol translocating the androgen receptor in 
pre-puberal and adult rats (Table 4 and 5) along with a 
somewhat lesser ability to translocate the estrogen, 
progesterone and glucocorticoid receptor (Table 5). 
It is generally agreed that danazol has weak 
, I 
androgenic and no estrogenic or anti-estrogenic prop-
etties, while its glucocorticoid and progestational 
effects are still somewhat controversial (Dmowski, 1979, 
Barbieri, et al, 1979, Dmowski et al, 1971 and Potts. et al, 
1974). Therefore, it must be concluded from this study 
that the strong binding and translocation of the androgen 
recept_or by danazol .is indicative of its androgenic 1 
responses elicited in vivo. The lower binding affinity 
·, 
• 
···.~ 
for the estrogen, progesterone and glucocorticoid 
receptor a'nd subsequent translocation of these receptors 
I 
may suggest the action of danazol on these receptor~. is 
I 
not sufficient to stimulate mRNA synthesis and thus1 
biological activity. 
Difficulty in obtaining good specific binding 
counts was a drawback of this procedure, It is sug-
gested that.higher counts may be obtained by a wash 
buffer of 1% Tween 80 in phosphate buffer, which has been 
shown to be more s.uccessful at diminishing the ·non- 1 
specific binding (Garala and· McGuire, 1978) than 
.phosphate buffer alone. 
In vivo studies o~ specific binding in intact rats 
treated with danazol (4 mg/kg body weight) shows a non-
significant reduction in all receptor binding in.uterine 
cytosol (see Table g), The estrogen binding in rats 
receiving danazol shows a 28% reduction from controls . 
. Progesterone was r·educed 23%,. DHT reduced ·17%, and· : 
corticosterone reduced 13% after dana~ol injections. 
These findings agree with similar studies done in the past 
several years. Barbieri found that danazol displaced DHT 
receptors in rat prostate, displaced progesterone in an 
estrogen-p.rimed rat _uterus, and that glucocorticoid 
receptors were displaced by danazol in rat liver cy~osol 
(Barbieri and Ryan, 1981). In another study, Potts 'showed 
that intact rats, pre-treated with danazol, showed 
~ignificarit inhibition in the pituitary and hypothaiamic 
uptake of 3H-labeled estradiol. (Potts, 1977). Musich, 
,, 
• 
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using a long term danazol at a high dosage, as opposed to 
low dosage as used in this study, showed a decrease inrE-R 
binding which may have been.due to the dose or the 
duration of treatment (Musich, et al., 1981). From a 
different ,viewpoint, Jenkin reported that danazol 
decreases the stimulatory effect on basal circulati~g 1 
' ' 
levels of estrogen and progesterone to the uterus thereby 
also directly effecting estrogen receptors in the tissue 
(Jenkin, 1980). Jenkin also stated that danazol competed 
with the uterine cytosol receptor for the estradiol and 
progesterone receptors. 
The effect .of ovariectomy on receptor. binding was 
only significant for estrogen receptors (see Table g). 
The 42% reduction of estrogen binding in ovariectomized 
1·ats was reduced to 45% in rats that received danazol 
injections in addition to the ovariectomy. This agrees 
with studies by Bohnet, et al. (1981) who reported that 
danazol prevented a compensatory increase in LH and FSH 
after ·ovariectomy. Potts found that ovariectomized rats 
treated.with danazol significantly inhibited pituita~y 
and hypothalamic uptake and thus binding of 3H-labele'd . 
estradiol (Potts, 1977). Th~se findings· disagree with 
findings by Wood who dimissed the local action by danazol 
I. 
on estrogen receptors when a 1000-fold excess of danazol 
did not ~ffect the 3H-estradiol binding to endometrial 
' 
• 
• • 
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cytosol (Wood, 1975). However, Wood's study was in vitro . -
%-" and many times in vivo and in vitro studies cannot be 
compared. 
I 
Other steroid receptor binding was not signif icaptl~ · 
reduce·d in Experiment. I. The 25% reduction. in progesterone 
binding after ovariectomy was nbt significant, a finding 
that diff~rs from a study by Peters who reported that in 
6varian hypofunction, a decrease in estrogen production 
would produce less progesterone receptors and thus 
reduced progesterone binding (Peters, et al., 1977). 
Danazol injections failed to influence a change in 
progesterone receptors after ovariectomy. 
With respect to mammary tissue, these studies were 
investigated with the hope that some data reflecting t:he 
influence of danazol on mammary receptors would be 
enlightening. However, from the data presented in Table g, 
mat:ure female rats, either intact or ovariectomized, 
8howed no significant change in the ability to bind 
steroid receptors; 
The effect of danazol on the reduction of uteririe 
and ovarian weights at low dose ( 4 mg/kg), long term 
(2 4. days), danazol treatment is consis.tant with that 
. ' . 
r 0 9orted by other investigators _(Jenkin, 1980) (Drn"w:;ki, 
iB?l). _This might be expected since th~ reported 
antigonadotropic effects o! danazo1 (Drnowski, 197t .• "i1d 
•· .... 
42 
the direct effect of d~nazol on inhibiting steroidogenesis 
(Barbieri ~nd Ryan, 1981) should lead to a reduction 
uterine weight. Adrenal weight reduction is also 
in 
I 
I 
consistent with Kitay's ~indings that estrogen~ have a 
' 
'stimulatory effect on the adrenal glands (Kitay; et ai., 
1963), and the more recent discovery that adrenals 
possess an androgen receptor which when bound by 
androgens, lowers adrenal weights (Rifka, 1978). Potts 
a1so reported a decrease in adrenal weights after dana.zol 
treatment (Potts, 1974)~ 
The controversy .over danazol's steroid binding to 
cytosol receptors remains but it has been seen that 
danazol has an effect on multiple classes of steroid 
receptors. Although discrepancies from established data 
have been noted, it should be remembered that in vivo· 
receptor studies may reflect the i~direct effects of 
danazo1. Therefore it should not be surprising that 
inconsistant receptor data might be seen. Even with in 
vitro studies discrepancies have been reported (Charnn~ss,· 
et al., 1980).. Another possibility for disagreement on 
receptor binding studies is th~t the metabolites of 
danazol are hormonally active and may play a part in 
receptor variability (Krey, 1981). These metabolites 
and their effect were not investigated. 
Since steroid receptors are thermolabi·le, unstaple 
proteins, possible variable resuits may be due to 
' 
'• ' 
·~· 
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incorrect sample storage or assay conditions such as : 
keepiqg the sample cold enough to enhance binding actfvity. 
Another consideration is that mariy receptor sites may! be 
nuclear binding sit~s, so.that cytoplasmic sites alon~ may 
not be an accurate display of the influence of danazol 
and/or ovariectomy on recepto~ binding. In any svent~ 
receptor studies are a molecular index of endocrine 
' '. 
function and dependency ·in a cell and improvements in· 
.quantitation of receptor complexes continue to be vital 
to hormone research and clinical therapy. 
In summary, evidence presented in this research 
indicates that danazol binds to and translocates estrogen, 
. i 
progesterone, glucocorticoid and androgen receptors in 
vitro, though not significantly, while showing the 
greatest success with the androgen receptor in·all 
tissues. The dose responsiveness of danazol was 
. effectively demonstrate;d by its ·increased competition; at 
pharmacological concentrations. Furthermore, the 
results indicated that danazol was most effective in 
translocating the androgen receptor 'in mammary tissue. 
The data from experiments performed in vivo after 
the injections of danazol at a dose of.4 mg/kg/14 days 
are summarized as follows: 
' . ' 
, .. . . . 
1). - A highly significant reduction of uterine 
weight in ovariectomized and intact rats. 
2). A highly significant reduction in uterine 
weight after ovariectomy. 
44 
3). A reduction in pooled adrertal weight (intact 
rats), with no additive weight reduction 
after ovariectomy. 
4). A highly significant reduction in ovarian 
weights after nine days of danazol 
inject ions. 
5). A non-significant decrease in all uterine 
receptors of danazol· treated rats compared· 
to intact rats. 
6). A significant difference in ovariectomized 
rats for estrogen receptors. 
7), Ovariectomy failed to reduce the concen-
tration of other steroid receptors. 
8). Mammary tissue was not significantly changed 
in its ability to bind steroid receptors.· . ' 
9), A general trend toward reduction of receptor 
binding in hypothalamic and adrenal glands. 
In light of this research, as well as evidence 
reported in the literature, the evaluation of receptor 
binding .and nuclear translocation data, will hopefully 
lead to a better understanding of normal steroid target 
cells, cancer modified cells and drug interaction with 
·each cell type. The ·major objectives·. of this research 
proposal have been met. The exclusion· of the use of car-
cinogenic tiss·ue was necessary due to the difficulty ~f 
the_ tec_hniques and the time necessary to develope these. 
' tecnhiques. The technique for mammary carcinoma indu~tion 
was developed for later research. 
• .. ,. 
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